GEN Exclusives

More »

GEN News Highlights

More »
Apr 19, 2012

MJFF Sponsors Phase Ib Trial with Sanofi's Parkinson Disease Candidate

  • The Michael J. Fox Foundation (MJFF) will fund a Phase Ib study with Sanofi’s PDE4 inhibitor AVE 8112 in patients with Parkinson disease. The study will be carried out in the U.S., and patient enrollment is expected to start later this year. Resulting data will essentially remain the property of MJFF, and will be shared with Sanofi, to determine future development plans for the drug.

    “AVE 8112 has shown promising pro-cognitive activity in preclinical models that could be of interest to the under-addressed cognitive aspects of Parkinson disease, an area of unmet need where a new treatment could make a tangible difference in patients’ lives,” comments Todd Sherer, Ph.D., MJFF CEO.

    Sanofi’s Genzyme business is separately carrying out Phase I development with an AAV-AADC gene therapy candidate for Parkinson disease. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Lab-Grown Vaginas

Which body part do you think will be successfully engineered in the lab next?